文献速递消化系统肿瘤支持与姑息治疗

循环L-精氨酸预测接受免疫检查点抑制剂治疗的癌症患者的生存

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
PubMed 文献 · Ann Oncol · 2022-07-16

在BIP(n=77)和PREMIS(n=296)两个晚期癌症队列及budigalimab单药1期研究中,基线血浆L-精氨酸(ARG)低水平(<42 μM)与更差的临床获益率、无进展生存和总生存显著独立相关。结直肠癌同系小鼠模型中高基线ARG组肿瘤排斥率显著高于低ARG组(85.7% vs 23.8%,P=0.004)。低ARG水平与髓系免疫细胞亚群程序性死亡配体1表达增加显著相关。

要点

  • 基线血浆ARG<42 μM与接受ICI治疗的晚期癌症患者更差的临床获益率、无进展生存和总生存显著独立相关。
  • 小鼠结直肠癌模型中高基线ARG组肿瘤排斥率85.7%,低ARG组23.8%(P=0.004)。
  • 低ARG水平与髓系免疫细胞亚群PD-L1表达增加显著相关。

核心结论

  • 基线ARG水平可预测ICI疗效,血浆ARG定量可能成为靶向ARG通路联合ICI的新型治疗方案的生物标志物。

研究设计与样本

  • 分析两个机构分子谱分析项目(BIP,NCT02534649,n=77;PREMIS,NCT03984318,n=296)中晚期癌症患者治疗前血浆样本及budigalimab单药1期首次人体研究(NCT03000257)患者样本。
  • 采用对ICI有应答的同系小鼠结直肠癌模型评估ARG水平与ICI疗效的相关性。
  • 利用匹配的外周血单个核细胞(PBMC)血浆样本,通过多重流式细胞术分析ARG水平与PBMC特征的相关性。

主要发现

  • 在发现队列和验证队列中,基线低ARG水平(<42 μM)均与更差的临床获益率、无进展生存和总生存显著且独立相关。
  • 临床前研究中,高基线ARG水平小鼠的肿瘤排斥率显著高于低ARG水平小鼠(85.7% vs 23.8%;P=0.004)。
  • PBMC免疫表型分析显示,低ARG水平与髓系多个免疫细胞亚群程序性死亡配体1表达增加显著相关。

关键数值与推荐

  • 基线低ARG水平定义为<42 μM。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the systemic approach to cancer treatment. Most patients receiving ICIs, however, do not derive benefits. Therefore, it is crucial to identify reliable predictive biomarkers of response to ICIs. One important pathway in regulating immune cell reactivity is L-arginine (ARG) metabolism, essential to T-cell activation. We therefore aimed to evaluate the association between baseline plasma ARG levels and the clinical benefit of ICIs. PATIENTS AND METHODS: The correlation between ARG levels and clinical ICI activity was assessed by analyzing plasma samples obtained before treatment onset in two independent cohorts of patients with advanced cancer included in two institutional molecular profiling programs (BIP, NCT02534649, n = 77; PREMIS, NCT03984318, n = 296) and from patients in a phase 1 first-in-human study of budigalimab monotherapy (NCT03000257). Additionally, the correlation between ARG levels and ICI efficacy in preclinical settings was evaluated using a syngeneic mouse model of colorectal cancer responsive to ICIs. Using matched peripheral blood mononuclear cell (PBMC) plasma samples, we analyzed the correlation between ARG levels and PBMC features through multiplexed flow cytometry analysis. RESULTS: In both discovery and validation cohorts, low ARG levels at baseline (<42 μM) were significantly and independently associated with a worse clinical benefit rate, progression-free survival, and overall survival. Moreover, at the preclinical level, the tumor rejection rate was significantly higher in mice with high baseline ARG levels than in those with low ARG levels (85.7% versus 23.8%; P = 0.004). Finally, PBMC immunophenotyping showed that low ARG levels were significantly associated with increased programmed death-ligand 1 expression in several immune cell subsets from the myeloid lineage. CONCLUSIONS: We demonstrate that baseline ARG levels predict ICI response. Plasma ARG quantification may therefore represent an attractive biomarker to tailor novel therapeutic regimens targeting the ARG pathway in combination with ICIs.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Peyraud F, Guégan JP, Bodet D, et al. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. Ann Oncol. 2022. PMID: 35850444. doi:10.1016/j.annonc.2022.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。